Abstract: A production of a drug, wherein the drug is specific for SH-SY5Y neuroblastoma cancer by loading caffeic acid phenethyl ester (CAPE) to a plurality of microvesicles that a specialized skin cell leaves into a nutrient solution. The objective of the present invention is to provide a cell-specific targeted vesicle development by loading the CAPE to the plurality of microvesicles obtained as a result of culturing and subsequent specialization of a plurality of tissue cells; and to use the CAPE at lower concentrations compared to a state of the art applications to minimize a toxicity of the CAPE to both a plurality of cells other than a plurality of targeted cells and a body.
Abstract: Provided are a method for preparing liposomes comprising ultrasound reactive microbubbles for drug delivery, comprising (a) a step of producing ultrasound reactive microbubbles comprising an inert gas therein and having a first shell formed on the outer surface thereof, followed by forming a uniform size distribution of the ultrasound reactive microbubbles through an extruder; and (b) a step of producing liposomes comprising the ultrasound reactive microbubbles distributed in a uniform size and a medicament therein and having a second shell formed on the outer surface thereof, followed by forming a uniform size distribution of the liposomes through an extruder; and a liposome using same.
Type:
Grant
Filed:
March 20, 2019
Date of Patent:
November 22, 2022
Assignees:
BIOINFRA LIFE SCIENCE INC., PACIFIC SYSTEM CO., LTD.
Inventors:
Chui Woo Kim, Dong Hee Park, Jong Ho Won
Abstract: A Magnetic Resonance Imaging (MRI) enhancement agent includes a plurality of particles, each particle including: a metal core; a dielectric shell disposed on the metal core comprising at least one MRI contrast agent; and a metal shell disposed on the exterior surface of the dielectric shell that encapsulates the dielectric shell.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
November 22, 2022
Assignees:
WILLIAM MARSH RICE UNIVERSITY, BAYLOR COLLEGE OF MEDICINE
Inventors:
Nancy J. Halas, Ciceron Ayala-Orozco, Sandra Bishnoi, Luke Henderson, Oara Neumann, Robia Pautler, Peter Nordlander
Abstract: The present invention relates to extended release microparticles comprising a drug, and a preparation method therefor, and when the extended release microparticles comprising a drug are administered in order to replace conventional drugs that should be administered daily or monthly, the drug administration effect can be continuously maintained for one week to three months. In addition, the drug administration effect is maintained for a long time and, simultaneously, microparticles are prepared so as to have the average diameter of a fixed micro-size, and thus an effective drug concentration can be constantly maintained by controlling the release of the drug from the microparticles, and a foreign body sensation and pain can be reduced during drug administration since microparticles having a uniform size are included during application as an injectable drug.
Abstract: The present invention relates to a stable and clear microemulsion comprising: an oil phase comprising an hydrophobic active ingredient; an aqueous phase; and a surfactant system comprising: a non-ionic primary surfactant system; a first non-ionic co-surfactant system, and a second non-ionic co-surfactant system.
Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.
Abstract: A preparation method for a liposome having the ability to stably encapsulate an active ingredient is provided. The preparation method includes providing a mixture and homogenizing the mixture at 300 bar-400 bar to form a liposome suspension. The mixture includes 0.1 wt % of lecithin, 2 wt %-5 wt % of Arabic gum and 63.9125 wt %-97.9 wt % of a solvent. The liposome suspension includes a plurality of liposomes.
Abstract: Shampoo compositions having an anionic surfactant, cationic deposition polymer, sheet-like microcapsules and an aqueous carrier. The shampoo composition delivers both good in use benefits, while maintaining a consumer desirable appearance. The sheet-like microcapsules can also contain perfumes, extracts, dyes, colorants, and/or benefit agents.
Type:
Grant
Filed:
December 13, 2019
Date of Patent:
November 15, 2022
Assignee:
The Procter & Gamble Company
Inventors:
Mark Anthony Brown, Pallavi Mohan Keole, David Scott Dunlop, Marco Caggioni
Abstract: Antimicrobial compositions and methods for depositing or coating the antimicrobial or antibacterial compositions on a substrate to prevent microbial adhesion are provided. The antimicrobial composition may include a cationic polymer having a poly-allylamine backbone. A portion of the poly-allylamine backbone may be functionalized with at least one of a guanidine functional group and a biguanide functional group.
Type:
Grant
Filed:
April 13, 2020
Date of Patent:
November 8, 2022
Assignee:
Colgate-Palmolive Company
Inventors:
Carl Myers, Carlo Daep, Lynette Zaidel, James Masters, Russell Composto, Hyun-Su Lee
Abstract: An anhydrous stick composition, including deodorant active, an antiperspirant active, or a combination thereof; a carrier; a structurant; and a cyclodextrin perfume complex, comprising cyclodextrin and a perfume, wherein the perfume comprises perfume raw materials and 10% or more, by weight of the perfume, of the perfume raw materials have: a cyclodextrin complex stability constant of about 3.0 or less, a C log P of about 2.5 or less; and a weight average molecular weight of about 200 Daltons or less.
Type:
Grant
Filed:
September 6, 2017
Date of Patent:
November 8, 2022
Assignee:
The Procter & Gamble Company
Inventors:
David Arthur Sturgis, Jianjun Justin Li, Marc Adam Flickinger, Virginia Tzung-Hwei Hutchins, Steven Louis Diersing, Steven Michael Wujek
Abstract: Provided is a sulfate-free surfactant system which is particularly suitable for use in personal hygiene products. The sulfate-free surfactant system comprises a liquid comprising an organic phase and a solvent wherein the organic phase comprises glyceride and surfactant and the liquid comprises: 4-40 wt % glyceride wherein the glyceride is the condensation reaction product of at least 1.10 moles of a mixture of acids to no more than 2.1 moles of mixture of acids per mole of glycerin; wherein mixture of acids comprises: at least 0.275 to no more than 0.990 moles of a first acid comprising a branched acid with 16-20 aliphatic carbons; at least 0.250 to no more than 0.810 moles of a second acid comprising an alkyl acid with 9-11 carbons; and at least 0.250 to no more than 0.810 moles of a third acid comprising an alkyl acid with 7-9 carbons wherein the third acid has a lower molecular weight than the second acid; and 6-45 wt % surfactant; and wherein the liquid has a BYV of at least 50 dyn/cm2.
Abstract: Nanoparticles coated with extracellular matrix (ECM) are provided, in some aspects, for the delivery of a therapeutic protein, nucleic acid, or drug. In some embodiments, the nanoparticles are delivered to a subject via inhalation or aerosol delivery. Also provided, in some aspects, are methods for treating acute lung injury comprising administering ?-Klotho (?Klotho) protein or DNA to a subject.
Type:
Grant
Filed:
July 8, 2016
Date of Patent:
November 8, 2022
Assignee:
The Board of Regents of The University of Texas System
Inventors:
Connie Hsia, Yi Hong, Orson W. Moe, Kytai Nguyen
Abstract: Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.
Type:
Grant
Filed:
September 29, 2016
Date of Patent:
November 1, 2022
Assignee:
The University of Chicago
Inventors:
Jeffrey A. Hubbell, David Scott Wilson, Sachiko Hirosue
Abstract: The present invention provides a pharmaceutical composition for subcutaneous administration comprising a blood factor and a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, wherein the blood factor is not encapsulated in said colloidal particle.
Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.
Type:
Grant
Filed:
August 26, 2019
Date of Patent:
October 18, 2022
Assignee:
CURADIGM SAS
Inventors:
Matthieu Germain, Marie-Edith Meyre, Agnès Pottier, Laurent Levy
Abstract: An object is to achieve a nanostructure that has structural stability and temperature responsivity. Provided is a nanostructure which is a hollow body constituted by a wall, the wall including a first region and a second region, the first region being formed from an assembly of a plurality of first amphiphilic molecules containing a hydrophilic block and a hydrophobic block, the second region being formed from an assembly of a plurality of second amphiphilic molecules which are different from the first amphiphilic molecules, the first region being arranged to be in its solid phase at a phase transition temperature at which the second region of the wall transitions from its solid phase to its liquid phase.
Abstract: A composition including a plant medium and a poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The composition may include one or more nutrients. The composition may be in a solid form, a fluid form, or a combination thereof. The poly-oxygenated aluminum hydroxide is soluble in a fluid. In one embodiment, the poly-oxygenated metal hydroxide composition may have particles having a diameter of 212 ?m or less, and which may be homogeneous.
Type:
Grant
Filed:
September 18, 2020
Date of Patent:
October 4, 2022
Assignee:
HEMOTEK, LLC
Inventors:
Caree L. Woodmansee, Robert A. Woodmansee, John W. Woodmansee, Jr., William E. Harmon
Abstract: Provided is a tissue staining composition containing carbon particles having a mean particle diameter less than 0.3 ?m in diameter (optionally less than 0.2 ?m in diameter) together with one or more agents that maintain the carbon particles in suspension (for example, an anti-settling agent and/or surfactant). In certain circumstances, the anti-settling agent may also have mucoadhesive properties. The tissue staining composition is visually dark and does not disperse rapidly when introduced into regions of tissue of interest making it ideal for marking the regions that can be visualized clearly and over prolonged periods of time via, for example, direct visualization, endoscopic or laparoscopic inspection. The invention also provides methods of making and using the tissue staining composition for marking regions of tissue of interest, for example, gastrointestinal tissue, as well as other tissues.
Type:
Grant
Filed:
August 29, 2017
Date of Patent:
September 27, 2022
Assignee:
GI SUPPLY
Inventors:
Mary Jo Timm, Robert G. Whalen, Amy A. Cameron, Patrick Lee
Abstract: Systems and methods for preparing synthetic osteoinductive bone grafts are provided in which a porous ceramic granule, which may be incorporated within a biocompatible matrix material, is loaded with an osteoinductive agent. Loading of granules is facilitated in some cases by the use of low-pH buffers and pre-treatments.
Type:
Grant
Filed:
October 4, 2018
Date of Patent:
September 27, 2022
Assignee:
BIOVENTUS, LLC
Inventors:
Eric Vanderploeg, Howard Seeherman, Christopher G. Wilson, John Wozney, Christopher T. Brown, John A. Kambouris
Abstract: A chronically implanted medical device is disclosed that has an outermost layer formed from a conjugate of a polymer with lipoic acid, the conjugate having free 1,2-dithiolane groups. It is contemplated that this layer scavenges reactive oxygen species, i.e. acts as an antioxidant, and thus reduces inflammation and other adverse effects around the implant itself.
Type:
Grant
Filed:
August 18, 2020
Date of Patent:
August 30, 2022
Assignee:
Battelle Memorial Institute
Inventors:
Gaurav Sharma, Ramanathan S. Lalgudi, Chad E. Bouton